Home - National Multiple Sclerosis Society

Skip to navigation Skip to content
National MS Society
Email not displaying correctly? View it in your browser.
National MS Society eNews October 2009
FDA Advisory Panel OKs Fampridine-SR

First-ever oral medication specifically for MS

Fampridine-SR would treat difficulty walking

On October 14, an FDA advisory committee recommended Fampridine-SR for approval. The FDA is expected to make a final decision on or before October 22. The expected decision will make Fampridine-SR (with the proposed brand name Amaya) the first medication ever approved specifically to treat an MS symptom.

In phase-III clinical trials, Fampridine-SR was found to improve walking speed in people with MS. While the studies mainly measured gait improvement, some participants said they felt less disabled during their daily activities. The drug, developed by Acorda Therapeutics, works by blocking tiny potassium channels on nerve surfaces, which may temporarily enhance nerve signaling.

Jackie Havner and Gracie
Jackie Havner and her granddaughter Gracie. Jackie, diagnosed with MS in 1965, was among the consumers testifying about benefits of Fampridine.

Filling a treatment gap

FDA approval would fill a large gap in current MS treatments, since this drug has shown benefit even in those with primary progressive MS, a form for which there are no approved disease-modifying therapies.

"Although we might think of difficulty walking as an isolated symptom of MS, this is far from true," said Nicholas LaRocca, PhD, in a statement for the committee. "It affects a large range of everyday activities." LaRocca is the vice president of Health Care Delivery and Policy Research at the Society.

While the FDA is not required to follow advisory committee recommendations, it almost always does.

More about the decision
More about Amaya (fampridine)
More about gait problems in MS

Meet Deena LisakDeena Lisak
Offers “Ask a Nurse” in Michigan
Meet Rana RussellRana Russell Juggles family, work, service and her MS in Texas
Meet Amy Van MeterAmy Van Meter Lobbies for access in California
eNews View Our Heading
Magazine for Kids
Donate Now
Become a Fan on Facebook Follow us on Twitter View our videos on YouTube Become a Friend on MySpace
Some losses, some gains at major European MS research meeting Some losses, some gains at major European MS research meeting

The 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (called ECTRIMS) was held September 9-12, 2009, in Dusseldorf, Germany. Good news centered on the progress of oral MS drugs in clinical trials, while disappointments mostly involved novel therapeutic agents, such as lamotrigine, an epilepsy drug.


Click to view videos.Who provides professional care for people with Progressive MS?
Meet a primary care physician, social worker, neuropsychologist, psychologist, speech/language pathologist, occupational therapist, physical therapist, physiatrist, nutritionist, and an MS nurse. Hear about what they do.


This communication is partially sponsored through the generous support of Novartis Pharmaceuticals Corporation; Teva Pharmaceuticals, Inc.; Genentech and Biogen Idec.

NovartisTeva Pharmaceuticals, Inc.

Shop at the Society Store       Join a Walk MS Event       Join a Bike MS Event

National MS Society | View as Web page | Subscribe | Legal Notice/Privacy Policy | Email Preferences | Unsubscribe

MS stops people from moving. The National MS Society exists to make sure it doesn’t. We are a collective of passionate individuals, moving together to create a world free of MS.

Please do not reply to this email as we are unable to quickly respond to messages sent to this address. To receive information about living with MS, Bike MS or Walk MS — or to contact National MS Society staff in your area — please
visit our Web site.

Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at http://www.nationalmssociety.org/ or 1-800-344-4867.

National Multiple Sclerosis Society | 733 Third Avenue | New York, NY | 10017

This message was sent to . To ensure that you continue to receive our emails, please add us to your address book.